The FDA is pursuing cannabinoid medicines through a federal pathway while challenging the existing rescheduling order regarding marijuana.
10 reports, 4 independent
Updated Jul 9
Gone quiet
Reached 2 outlets in its first 24 hours
- Reports
- 10
- Developments
- 3
- Repetition
- 80%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
The FDA is pursuing cannabinoid medicines through a federal pathway while challenging the existing rescheduling order regarding marijuana.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.- MMJ International Holdings is pursuing FDA-approved cannabinoid medicines.Sub-event
FDA found that a state medical marijuana system lacks clinical evidence and federal drug development standards.1 source
FDA pursues cannabinoid medicines via federal pathway, challenging marijuana rescheduling order.1 source
Keep exploring
The entities involved
Related events
- Agencies (FDA and DEA) implement a regulatory shift concerning cannabis.
- A DOJ/DEA order moves FDA-approved cannabis products, which subsequently affects Nasdaq's new listing pathway.
- FDA approval enables commercial opportunity involving CBRE Group.
- FDA rule changes are causing delays in product approval, leading to the process exceeding Congressional mandated timeframes.
- Litigation regarding FDA approval process.